<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02022826</url>
  </required_header>
  <id_info>
    <org_study_id>MA-501</org_study_id>
    <nct_id>NCT02022826</nct_id>
  </id_info>
  <brief_title>Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis</brief_title>
  <official_title>Clinical Management With SmartPill Motility Monitoring System and Validation of the SmartPill Five Hour Cutoff in Patients With Symptoms of Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic - MITG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is designed to validate use of the SPM for diagnosis of delayed gastric
      emptying in patients with symptoms of gastroparesis and assess impact of a SmartPill study on
      patient management in the gastroparetic populations. Patients with symptoms of gastroparesis
      will be recruited.

      Patients will undergo concurrent gastric scintigraphy and SPM testing to determine the
      presence or absence of delayed gastric emptying based on predetermined diagnostic cutoffs for
      each technique.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    sponsor internal decision
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Per Patient Device Agreement Between SmartPill Motility Monitoring System Gastric Emptying Time &amp; Gastric Emptying Scintigraphy Test in Patients With Symptoms of Gastroparesis</measure>
    <time_frame>an expected average of two weeks from study procedure</time_frame>
    <description>Per patient device agreement for the diagnosis of delayed gastric emptying between SmartPill Motility Monitoring System (SPM) gastric emptying time (GET &gt;5 hours) and the non-reference standard, gastric Emptying scintigraphy test (&gt;10% retention of a solid meal at 4 hours) in patients with symptoms of gastroparesis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Agreement Between Gastric Emptying Time of SmartPill Capsule and Gastroduodenal Contractility and Percent of Radiolabeled Meal Retained at 4 Hours on Scintigraphy for Severe Gastroparesis</measure>
    <time_frame>an expected average of two weeks from study procedure</time_frame>
    <description>Agreement between Gastric emptying time of SmartPill capsule (GET&gt;8hrs= severe) and gastroduodenal contractility and percent of radiolabeled meal retained at 4 hours on scintigraphy (&gt;35% = severe)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>SmartPill Monitoring System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SmartPill Monitoring System</intervention_name>
    <arm_group_label>SmartPill Monitoring System</arm_group_label>
    <other_name>SPM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between ages of 18-80 years of age with symptoms of gastroparesis
             for at least 12 weeks.

          -  Presenting with 2 or more of the following symptoms or signs which, in the opinion of
             the site investigator, are suggestive of a diagnosis of gastroparesis:

               -  1 Nausea, vomiting, or retching (dry heaves)

               -  2 Postprandial fullness or early satiety

               -  3 Bloating or visible abdominal distention

               -  4 Postprandial discomfort or pain

          -  Ability to stop proton pump inhibitors for 7 days and histamine2 receptor antagonists,
             prokinetic agents, narcotic agents, anticholinergic drugs, and cannabinoids 3 days
             prior to SPM and gastric scintigraphy testing.

          -  No evidence of metabolic disease (hypothyroidism, uncontrolled diabetes [hemoglobin
             A1c &gt;10% within the past 6 months], electrolyte imbalance).

          -  An upper endoscopy or upper gastrointestinal barium series within the past 2 years
             showing no organic disease that is potentially causative of symptoms.

          -  High probability of compliance and completion of study.

        Exclusion Criteria:

          -  Participation in previous SmartPill clinical trials.

          -  Previous history of bezoars (the presence of retained liquid, bile, or small amounts
             of poorly organized food residue is permitted).

          -  Dysphagia to solid food or pills.

          -  Prior surgery involving the luminal gastrointestinal tract (cholecystectomy,
             appendectomy, and hysterectomy are permitted if performed &gt; 3 months prior to SPM
             test).

          -  Any abdominal or pelvic surgery within the past 3 months

          -  Known or history of inflammatory bowel disease.

          -  History of diverticulitis, diverticular stricture, and other intestinal strictures.

          -  Chronic daily use of nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, etc.)

          -  Tobacco or alcohol use within eight hours prior to capsule ingestion.

          -  BMI &gt; 40 kg/m2.

          -  Allergies to eggs, bread, or jam.

          -  Females of childbearing age who are not practicing birth control and/or are pregnant
             or lactating. (Urine pregnancy testing will be performed on female subjects of
             child-bearing potential prior to capsule ingestion and gastric scintigraphy).

          -  Use of cardiac medical devices such as pacemakers and defibrillators (gastric
             stimulators, bladder stimulators, spinal stimulators, medication infusion devices,
             insulin pumps, continuous glucose monitors are permitted).

          -  Uncontrolled diabetes with a hemoglobin A1c &gt;10%.

          -  Patient is expected to undergo MRI examination within 7 days after ingestion of the
             capsule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Braden Kuo, Dr.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Digestive Health</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami miller school of Medicin</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinsearch,LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2013</study_first_submitted>
  <study_first_submitted_qc>December 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2013</study_first_posted>
  <results_first_submitted>August 20, 2017</results_first_submitted>
  <results_first_submitted_qc>November 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 30, 2017</results_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroparesis</keyword>
  <keyword>SmartPill Monitoring System (SPM)</keyword>
  <keyword>Gastric Emptying Scintigraphy (GES)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period- January 2014 March 2017; 11 academic and community centers within the US</recruitment_details>
      <pre_assignment_details>medication wash out period: Subjects instructed to discontinue agents that affect intragastric acidity including proton pump inhibitors for 7 days, histamine2 receptor antagonists for 3 days and antacids for 1 day prior to study including the day of SPM ingestion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SmartPill Monitoring System</title>
          <description>patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SmartPill Monitoring System</title>
          <description>patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="167"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="18" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>suspected gastroparesis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Per Patient Device Agreement Between SmartPill Motility Monitoring System Gastric Emptying Time &amp; Gastric Emptying Scintigraphy Test in Patients With Symptoms of Gastroparesis</title>
        <description>Per patient device agreement for the diagnosis of delayed gastric emptying between SmartPill Motility Monitoring System (SPM) gastric emptying time (GET &gt;5 hours) and the non-reference standard, gastric Emptying scintigraphy test (&gt;10% retention of a solid meal at 4 hours) in patients with symptoms of gastroparesis</description>
        <time_frame>an expected average of two weeks from study procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SmartPill Monitoring System</title>
            <description>patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test</description>
          </group>
        </group_list>
        <measure>
          <title>Per Patient Device Agreement Between SmartPill Motility Monitoring System Gastric Emptying Time &amp; Gastric Emptying Scintigraphy Test in Patients With Symptoms of Gastroparesis</title>
          <description>Per patient device agreement for the diagnosis of delayed gastric emptying between SmartPill Motility Monitoring System (SPM) gastric emptying time (GET &gt;5 hours) and the non-reference standard, gastric Emptying scintigraphy test (&gt;10% retention of a solid meal at 4 hours) in patients with symptoms of gastroparesis</description>
          <units>percentage of agreement</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="69" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0052</p_value>
            <method>McNemar</method>
            <param_type>percentage of agreement</param_type>
            <param_value>76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>69</ci_lower_limit>
            <ci_upper_limit>83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Agreement Between Gastric Emptying Time of SmartPill Capsule and Gastroduodenal Contractility and Percent of Radiolabeled Meal Retained at 4 Hours on Scintigraphy for Severe Gastroparesis</title>
        <description>Agreement between Gastric emptying time of SmartPill capsule (GET&gt;8hrs= severe) and gastroduodenal contractility and percent of radiolabeled meal retained at 4 hours on scintigraphy (&gt;35% = severe)</description>
        <time_frame>an expected average of two weeks from study procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SmartPill Monitoring System</title>
            <description>patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test</description>
          </group>
        </group_list>
        <measure>
          <title>Agreement Between Gastric Emptying Time of SmartPill Capsule and Gastroduodenal Contractility and Percent of Radiolabeled Meal Retained at 4 Hours on Scintigraphy for Severe Gastroparesis</title>
          <description>Agreement between Gastric emptying time of SmartPill capsule (GET&gt;8hrs= severe) and gastroduodenal contractility and percent of radiolabeled meal retained at 4 hours on scintigraphy (&gt;35% = severe)</description>
          <units>percentage of agreement</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="87" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>McNemar</method>
            <param_type>precentage of agreement</param_type>
            <param_value>92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87</ci_lower_limit>
            <ci_upper_limit>96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected from beginning of enrollment to last patient last visits: January 2014-March 2017 (2 years and 3 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SmartPill Monitoring System</title>
          <description>patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>uncontrolled high blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>exacerbation of pre-existing condition secondary to gastroparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>capsule retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right Hip Replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>kidney translant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>laproscopic-assisted vaginal historectomy and right salpingo-oophorectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dumping syndrome</sub_title>
                <description>Dumping syndrome</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>extreme pain and bloating</sub_title>
                <description>extreme pain and bloating</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right Hip Replacement</sub_title>
                <description>body aches and arthralgia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain Aneurysm</sub_title>
                <description>Brain Aneurysm</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>facial droop, ER visit; diagnosed with Bell's palsy</sub_title>
                <description>facial droop, ER visit; diagnosed with Bell's palsy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>kidney translant</sub_title>
                <description>pregnancy</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>labioplasty with bilateral simple partial vulvectomy</sub_title>
                <description>labioplasty with bilateral simple partial vulvectomy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respitory Infection</sub_title>
                <description>Upper Respiratory Infection</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michal Kedar-Datel</name_or_title>
      <organization>Medtronic</organization>
      <phone>+972-4-9097952</phone>
      <email>michal.kedar-datel@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

